期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 20, 期 24, 页码 7849-7863出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v20.i24.7849
关键词
Pancreatic neoplasms; Molecular targeted therapy; Genomics; Tissue banks; Chemotherapy
资金
- NHMRC
- Pancare Australia
- Sydney Catalyst
- Royal Australasian College of Physicians
- NHMRC Programme Grant
- Cancer Research UK [17263] Funding Source: researchfish
The treatment of advanced pancreatic cancer has not moved much beyond single agent gemcitabine until recently when protocols such as FOLFIRINOX (fluorouracil, leucovorin, irinotecan and oxaliplatin) and nab-paclitaxel-gemcitabine have demonstrated some improved outcomes. Advances in technology especially in massively parallel genome sequencing has progressed our understanding of the biology of pancreatic cancer especially the candidate signalling pathways that are involved in tumourogenesis and disease course. This has allowed identification of potentially actionable mutations that may be targeted by new biological agents. The heterogeneity of pancreatic cancer makes tumour tissue collection important with the aim of being able to personalise therapies for the individual as opposed to a one size fits all approach to treatment of the condition. This paper reviews the developments in this area of translational research and the ongoing clinical studies that will attempt to move this into the everyday oncology practice. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据